The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Abstract
OBJECTIVE: Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia. The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses. METHOD: Twelve patients with schizophrenia were randomly assigned to 5, 10, 15, or 20 mg/day of olanzapine in a prospective fashion. Three other subjects taking 30-40 mg/day were also included. Once steady-state plasma levels were achieved, dopamine D2 and serotonin 5-HT2 receptors were assessed by using [11C]raclopride and [18F]setoperone positron emission tomography imaging, respectively. Ratings of clinical status, extrapyramidal side effects, and prolactin levels were also obtained. RESULTS: Olanzapine induced near saturation of the 5-HT2 receptors, even at 5 mg/day. Its D2 occupancy increased with dose: patients taking 5-20 mg/day showed 43%-80% D2 occupancy, while patients taking 30-40 mg/day showed 83%-88%. CONCLUSIONS: Olanzapine is a potent 5-HT2 blocker and shows a higher 5-HT2 than D2 occupancy at all doses. However, its D2 occupancy is higher than that of clozapine and similar to that of risperidone. In the usual clinical dose range of 10-20 mg/day, its occupancy varies from 71% to 80%, and this restricted range may explain its freedom from extrapyramidal side effects and prolactin elevation. However, doses of 30 mg/day and higher are associated with more than 80% D2 occupancy and may have a higher likelihood of prolactin elevation and extrapyramidal side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R., Graffeo, K. A., & Thieme, M. E. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Janicak P, Javaid J, Sharma R, Leach A, Easton M, Dowd S, Davis J, Dowd S, Davis J: Haloperidol dose/response relationship—results from a random-assignment, double blind study (abstract). Neuropsychopharmacology 1994; 10:106S
Cited by
Sorted by citations
Items 301–372 of 372
Potential therapeutic targets for schizophrenia
Wong, A. H. C., Sanyal, S., Knapp, M., & Tol, H. H. M. V. (1999) · Emerging Therapeutic Targets · doi:10.1517/14728222.3.4.571 · Cited by 2
Monoterapia versus Politerapia en el tratamiento de la Psicosis: ¿Con qué nos quedamos?
Contreras, E. L., & Álvarez, J. L. F. (2011) · Revista Clínica de Medicina de Familia · doi:10.4321/s1699-695x2011000200009 · Cited by 2
Lykouras, L. P., Markianos, M., Hatzimanolis, J., & Oulis, P. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00183-4 · Cited by 2
Central Nervous System Drug Evaluation Using Positron Emission Tomography
Sekine, M., Maeda, J., Shimada, H., Nogami, T., Arakawa, R., Takano, H., Higuchi, M., Ito, H., Okubo, Y., & Suhara, T. (2011) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2011.9.1.9 · Cited by 2
Los antipsicóticos atípicos: una revisión
García‐Anaya, M., Apiquián, R., & Fresán, A. (2001) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 2
Pharmacogenomics Applications in Psychiatric Disorders
Lencz, T., & Malhotra, A. K. (2008) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-439-1_17 · Cited by 2
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50023-1 · Cited by 2
Dopamine and Response to Antipsychotic Medication
Ntephe, C., & Demjaha, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_14 · Cited by 2
The Analysis of Antipsychotic Drugs in Human Biosamples by LC-MS
Saar, E., Gerostamoulos, D., Drummer, O. H., & Beyer, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3828-1_8 · Cited by 2
Gründer, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_55 · Cited by 2
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
Uchida, H., Kim, E., Jarskog, L. F., Fleischhacker, W. W., Remington, G. J., & Lieberman, J. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_134-1 · Cited by 2
Self-citationProlactinémie et médicaments psychotropes actuels
Lancelin, F., Poirier-Bègue, E., Mestre, B., Carre, C., Baldach, A., & Piketty, M. (2001) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/s0923-2532(01)80021-1 · Cited by 2
Dopaminergic and glutamatergic influences in the systems biology of schizophrenia
Tamminga, C. A., & Medoff, D. R. (2003) · CRC Press eBooks · doi:10.3109/9780203427347-11 · Cited by 2
Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission
Munkholm, K., Jørgensen, K. J., & Paludan‐Müller, A. S. (2019) · JAMA · doi:10.1001/jama.2019.17691 · Cited by 2
Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics
Lako, I. M., Liemburg, E. J., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000172 · Cited by 2
Park, B., Yoo, Y.-J., Kim, R.-H., Jang, Y.-J., Lee, J. H., Kim, T. H., Lee, Y., Hwang, J. H., Kim, I., Hwang, H. P., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3145323/v1 · Cited by 2
Tamrakar, S. M., Diaz, A. M., Nevarez‐Flores, A. G., & Castle, D. J. (2024) · Australasian Psychiatry · doi:10.1177/10398562241283156 · Cited by 1
Pandey, A., Sharma, R. K., Dixit, S., & Tripathi, S. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_281_25 · Cited by 1
Palangi, M. G., Ahangar, H., Sakhaie, N., & Yasami, P. (2026) · Clinical Case Reports · doi:10.1002/ccr3.71987 · Cited by 1
Review article: CLINICAL PHARMACOLOGY OF ATYPICAL ANTIPSYCHOTICS: AN UPDATE
Maurí, M., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., & Pace, C. D. (2014) · Cited by 1
McCutcheon, R. A., Kaar, S. J., & Howes, O. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.011 · Cited by 1
Drug Treatment of the Psychoses
Rogers, J. P., Chesney, E., Morrison, P., & Gaughran, F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.012 · Cited by 1
Pharmacodynamic gene polymorphism and adverse drug reactionsthen applying antipsychotic drugs
Zastrozhin, M. S., Sychev, D. A., Гришина, Е. А., Savchenko, L. M., & Bryun, E. A. (2017) · World Journal of Personalized Medicine · doi:10.14341/wjpm9265 · Cited by 1
Serotonin in Central Cardiovascular Regulation
Pilowsky, P. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-800050-2.00016-4 · Cited by 1
Challenges of managing a first episode of pediatric catatonia
Lim, C. T., & Stern, J. L. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.005 · Cited by 1
Olanzapine-Induced Tardive Blepharospasm: A Case Report
Poh, Y. C., Wahab, S. B., Theng, Y. M., Muthukrishnan, A., & Murugan, K. (2019) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.91066 · Cited by 1
Červenka, S., & Farde, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-35206-6_8 · Cited by 1
Imaging drug action in schizophrenia: research update
Laruelle, M. A., & Abi‐Dargham, A. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)80003-2 · Cited by 1
‘Atypical’ antipsychotics: where does ziprasidone fit?
Remington, G. J. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.1.13 · Cited by 1
Self-citationIn Vivo Imaging of Dopamine Receptors
Abi‐Dargham, A., & Laruelle, M. A. (2009) · The Receptors · doi:10.1007/978-1-60327-333-6_15 · Cited by 1
Biochemical alterations in schizophrenia
Glenthoj, B. Y., Kristiansen, L. V., Rasmussen, H., & Oranje, B. (2009) · CRC Press eBooks · doi:10.3109/9781420080063-13 · Cited by 1
Bortolozzi, A. A., Díaz-Mataix, L., & Artigas, F. (2007) · Wiley eBooks · doi:10.1002/9783527619337.ch8 · Cited by 1
Gründer, G. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_30 · Cited by 1
Anderson, K. E., Tan, A. M., Feigin, A., Reilmann, R., Rosser, A., Raymond, L. A., Kostyk, S. K., Carsten Saft, C., Chen, K., Hand, R., et al. (2025) · medRxiv · doi:10.1101/2025.10.30.25339054 · Cited by 1
Neuroimaging of schizophrenia and its development
Keshavan, M. S., Diwadkar, V. A., Prasad, K. M. R., & Stanley, J. A. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511757402.013
PET studies on the mechanism of monoaminergic drugs
Nord, M. (2014) · Figshare
Enquête sur l’utilisation des antipsychotiques atypiques au Centre Hospitalier des Pays de Morlaix
Renan, X., Bertholom, C., Assicot, P., Feldman, D., & Milocheau, M. (2006) · Le Pharmacien Hospitalier · doi:10.1016/s0768-9179(06)75345-7
Reply to E. J. Harvey et al. — D2 receptor occupancy under recommended and high doses of olanzapine
Meisenzahl, E., Schmitt, G., Dresel, S. H. J., & Möller, H. ‐. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500308
Björkholm, C. (2013) · Figshare
Desai, P. (2014) · Texas ScholarWorks (Texas Digital Library)
[PET (positron emission tomography) research on schizophrenia].
Takano, A., & Suhara, T. (2006) · Folia Pharmacologica Japonica · doi:10.1254/fpj.128.177
Neto, A. F. R. (2016) · TDX (Tesis Doctorals en Xarxa)
The Effects of Atypical Antipsychotics on Implicit Reward Learning in Schizophrenia
Bradford, L. (2015) · QSpace (Queen's University Library)
Olanzapine - Focus on the Cardiometabolic Side Effects
Mitrović, M., Nikolic, T. R., Turnic, M., & Djurić, D. (2018) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2017-0054
Eficacia de los antipsicóticos: relación con la ocupación óptima de los receptores D2
Pani, L., Pira, L., & Marchese, G. (2007) · European psychiatry (Ed Española) · doi:10.1017/s1134066500004549
Extrastriatal dopamine D2/3 receptors in schizophrenia
Tuppurainen, H. (2011) · UEF eRepo (University of Eastern Finland)
Biochemical alterations in schizophrenia
Glenthoj, B. Y., Kristiansen, L. V., Rasmussen, H., & Oranje, B. (2009) · Medical psychiatry · doi:10.3109/9781420080063.011
Mendoza, J. E., & Foundas, A. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-36601-2_11
Carvajal, A., & Arias, L. H. M. (2000) · Side effects of drugs annual · doi:10.1016/s0378-6080(00)80012-4
Waldman, L., Richardson, B., Hamilton, J., & Thanos, P. K. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4020796
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01178-1
Parsey, R. V., Oquendo, M. A., Cooper, T. B., Arango, V., & Mann, J. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.008
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00135-2
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53266-4.50005-7
Pharmacokinetic and Pharmacodynamic Principles
Zernig, G., & Hiemke, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_1
Clinical Evolution of Tardive Cervical Dystonia from Antecollis to Retrocollis
Costa, O., Varanda, S., Carneiro, G., & Rodrigues, M. (2023) · Cureus · doi:10.7759/cureus.38565
Prevalence and Pattern of Olanzapine Emergent Obsessive–Compulsive Symptoms: A Cross-sectional Study
Mishra, D. K., Singh, U. P., Kishore, A., & Niranjan, V. (2023) · Apollo Medicine · doi:10.4103/am.am_105_23
Ballon, J. S., Nunes, J. C., & Salaheldin, K. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as27
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
Uchida, H., Kim, E., Jarskog, L. F., Fleischhacker, W. W., Remington, G. J., & Lieberman, J. A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_134
Self-citationAktuelle Schwerpunkte der Schizophrenieforschung
Möller, H. ‐. (2003) · Steinkopff eBooks · doi:10.1007/978-3-642-57417-7_2
n/a, N. (1998) · pharma-kritik · doi:10.37667/pk.1998.353
Long-Term Slowing of Progression in Huntington’s Disease with Pridopidine TreatmentPreprint
Reilmann, R., Tan, A. M., Rosser, A., Chen, K., Anderson, K. E., Kostyk, S. K., Feigin, A., Hand, R., Geva, M., & Hayden, M. R. (2026) · medRxiv · doi:10.64898/2026.02.13.26345490
Hu, W., Huang, B., Guo, X., Yin, X., Wang, X., Ji, Y., Zheng, Y., Gao, T., Shi, C., Yu, X., et al. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s603001
Mishra, A., Mishra, B. R., Maiti, R., & Hota, D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104944
Comparative Risk of Hyponatremia Among Patients Treated With Second-Generation Antipsychotics
Hatano, M., Koseki, T., Saito, T., & Yamada, S. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.28796
BindingDB Entry 50036996: Current and novel approaches to the drug treatment of schizophrenia.
BindingDB (2012) · UC San Diego · doi:10.7270/q24q7vqh
BindingDB (2023) · UC San Diego · doi:10.7270/q26m3bs8
Cornea-Hébert (1999) · doi:10.1002/(sici)1096-9861(19990628)409:2
Metadata
- Authors
- Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S.
- Venue
- American Journal of Psychiatry
- Published
- 1998-07-01
- Volume
- 155
- Issue
- 7
- Pages
- 921-928
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2163010981
- Cited by
- 370
- References
- 41
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 7 · 2014: 9 · 2013: 19 · 2012: 14
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- olanzapine, schizophrenia, dopamine D2 receptor occupancy, atypical antipsychotics, dose dependence, extrapyramidal symptoms, prolactin elevation, [11C]raclopride, clozapine, risperidone
- MeSH terms
- Olanzapine, Adult, Benzodiazepines, Carbon Radioisotopes, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorine Radioisotopes, Humans, Male, Pirenzepine, Prolactin, Pyrimidinones, Receptors, Serotonin, Salicylamides, Schizophrenia, Tomography, Emission-Computed, Antipsychotic Agents, Treatment Outcome, Receptors, Dopamine D2, Raclopride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
